Background: The diagnosis of acrodermatitis chronica atrophicans (ACA), the late cutaneous manifestation of Lyme borreliosis, can be challenging. Histologic changes in ACA have been described in a few studies from endemic countries, relying on cases documented by serology only.

Objectives: We sought to reassess the clinicopathological spectrum of ACA in a series of thoroughly documented cases.

Methods: Patients prospectively included in a national prospective study were selected on the basis of positive culture and/or polymerase chain reaction of a skin biopsy sample. The diagnosis of ACA was confirmed by reviewing the clinical and serologic data. Histopathological samples were carefully reviewed.

Results: Twenty patients were included. Unusual clinical features (ie, numerous small violaceous patches and equidistant small spinous papules with background faint erythema) were observed in 2 patients. Histopathological examination revealed a classic plasma cell-rich perivascular and interstitial pattern with telangiectases in 16 of 25 samples, whereas strikingly prominent granuloma annulare-like or lichenoid features were observed in 4 and 2 of 25 cases, respectively, and discrete nonspecific minor changes in 3 of 25 cases.

Limitations: The small number of patients was a limitation.

Conclusions: Genuine culture- and/or polymerase chain reaction-proven ACA can rarely present as numerous violaceous patches or cluster of spinous papules clinically, and as a granuloma annulare-like or lichenoid dermatosis histologically.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2015.10.046DOI Listing

Publication Analysis

Top Keywords

and/or polymerase
12
polymerase chain
12
clinicopathological spectrum
8
late cutaneous
8
lyme borreliosis
8
acrodermatitis chronica
8
chronica atrophicans
8
prospective study
8
culture- and/or
8
chain reaction
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!